Phase III Clinical Study of the Efficacy and Safety of 9MW0813 and Aflibercept (EYLEA®) in Patients With Diabetic Macular Edema (DME) in a Multicenter, Randomized, Double-blind, Parallel Active-controlled Study
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Aflibercept (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
- 13 Apr 2022 New trial record
- 05 Apr 2022 Status changed from not yet recruiting to recruiting.